Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites

Clicks: 223
ID: 269372
2007
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
The t(1/2) of the levosimendan metabolites was prolonged 1.5-fold and their AUC and C(max) were 2-fold in patients with severe CRF and ESRD patients undergoing haemodialysis as compared with healthy subjects. These results suggest that the dose should be reduced when levosimendan is used for the tre …
Reference Key
j2007clinicaleffect Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Puttonen J;Kantele S;Kivikko M;Häkkinen S;Harjola VP;Koskinen P;Pentikäinen PJ;;
Journal clinical pharmacokinetics
Year 2007
DOI DOI not found
URL
https://www.ncbi.nlm.nih.gov/pubmed/17328582
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't algorithms female male aged middle aged Clinical Trial area under curve half-life phase i heart rate / physiology protein binding blood pressure / physiology kidney function tests kidney failure renal dialysis / adverse effects* hydrazones / adverse effects pyridazines / adverse effects simendan pmid:17328582 doi:10.2165/00003088-200746030-00004 jaakko puttonen sampo kantele pertti j pentikäinen biotransformation cardiotonic agents / adverse effects cardiotonic agents / pharmacokinetics* hydrazones / pharmacokinetics* chronic / metabolism* pyridazines / pharmacokinetics*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.